US Stock MarketDetailed Quotes

NBIX Neurocrine Biosciences

Watchlist
  • 117.590
  • +1.690+1.46%
Close Feb 26 16:00 ET
  • 117.510
  • -0.080-0.07%
Pre 06:42 ET
11.72BMarket Cap35.74P/E (TTM)

Neurocrine Biosciences Key Stats

Neurocrine Biosciences Q4 2024 Earnings Date

Currency:USDFeb 6, 2025

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
629.44M
627.70M
-1.74M
Miss Est.
+22.17%
+21.84%
-0.28%
EPS
1.51
1.00
-0.51
Miss Est.
+5.01%
-30.56%
-33.87%
Strong Buy

Feb 26, 2025

Neurocrine Biosciences Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 20 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 652.537M--
--2025/Q1-- / 604.761M--
Feb 6, 20252024/Q4627.700M / 629.435M--
Oct 30, 20242024/Q3622.100M / 602.780M--
Aug 1, 20242024/Q2590.200M / 546.595M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 652.537M--
--2025/Q1-- / 604.761M--
Feb 6, 20252024/Q4627.700M / 629.435M--
Oct 30, 20242024/Q3622.100M / 602.780M--
Aug 1, 20242024/Q2590.200M / 546.595M--

Unlock Free Earnings Estimates

Neurocrine Biosciences Earnings Reports

Read more

Trending Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Feb 26, 2025

Strong Buy

  • Buy

    81.82%
  • Hold

    18.18%
  • Sell

    0.00%

Price Target

No Data